Zeatin is indispensable for the G2-M transition in tobacco BY-2 cells  by Laureys, Françoise et al.
Zeatin is indispensable for the G2-M transition in tobacco BY-2 cells
Franµoise Laureysa, Walter Dewittea, Erwin Wittersa, Marc Van Montagub, Dirk InzeŁc,
Harry Van Onckelena;*
aLaboratorium voor Plantenbiochemie en -fysiologie, Department of Biology, Universiteit Antwerpen (UIA), Universiteitsplein 1,
B-2610 Wilrijk, Belgium
bLaboratorium voor Genetica, Department of Genetics, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, B-9000 Ghent, Belgium
cLaboratoire AssocieŁ de l’Institut National de la Recherche Agronomique (France) and Department of Genetics,
Flanders Interuniversity Institute for Biotechnology, Rijksuniversiteit Gent, B-9000 Ghent, Belgium
Received 24 February 1998
Abstract The importance of N6-isoprenoid cytokinins in the
G2-M transition of Nicotiana tabacum BY-2 cells was investi-
gated. Both cytokinin biosynthesis and entry in mitosis were
partially blocked by application at early or late G2 of lovastatin
(10 WM), an inhibitor of mevalonic acid synthesis. LC-MS/MS
quantification of endogenous cytokinins proved that lovastatin
affects cytokinin biosynthesis by inhibiting HMG-CoA reduc-
tase. Out of eight different aminopurines and a synthetic auxin
tested for their ability to override lovastatin inhibition of mitosis,
only zeatin was active. Our data point to a key role for a well-
defined cytokinin (here, zeatin) in the G2-M transition of tobacco
BY-2 cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Comparison of the plant cell cycle regulation with animal
and yeast models has resulted in the appreciation of large
homologies, however with some plant-speci¢c cell cycle con-
trol mechanisms [1^6]. Families of cyclin dependent kinases
(CDKs) and their regulatory subunits (cyclins) [5^7] control
transitions through and between stages of the cell cycle, in the
animal as well as in the plant kingdom. According to Zhang
et al., it is in the direct coupling of mitotic control to hormo-
nal signals, that plant cells di¡er from somatic animal cells [8].
To enable plant cells to proceed through di¡erent stages of the
cell cycle, the continuous presence of both cytokinins and
auxins is essential [9]. The stimulating e¡ect of cytokinins
on cell division has been observed in numerous cases ranging
from the initiation of root primordia in planta to induction of
cell division in protoplast suspension cultures [9^14]. It has
been shown that cytokinins can control the cell cycle by stim-
ulating the tyrosine dephosphorylation of a tobacco p34cdc2-
like kinase [8,15] during mitosis as well as by regulating the
expression of the cdc2 gene [16]. Recent data point to a pos-
sibility for physical interaction between cytokinins and kinases
[17,18]. Structural cytokinin analogues such as olomoucine
[19,20] and roscovitine [21] were shown to act as competitive
inhibitors of speci¢c plant CDKs. A general conclusion
emerging from all these studies is that cytokinins are among
the major controlling factors of the cell cycle.
The rapid and cytokinin-autonomous cell cycle of
synchronised tobacco BY-2 cell suspension cultures [22]
makes them ideal tools to study cytokinin control mechanisms
on cell cycle progression. The cytokinin-autonomous charac-
ter of the BY-2 cells is linked to the capacity of these cells to
synthesise cytokinins [23,24]. Using LC-MS/MS techniques,
Redig et al. [25] were able to show a distinct transient accu-
mulation of Z-type cytokinins at G2-M transition.
It was the main aim of this study to determine the causal
relationship between the transient accumulation of Z-type
cytokinins and the entry in mitosis of BY-2 cells.
In order to investigate this relationship, lovastatin was
chosen as a putative inhibitor of cytokinin biosynthesis. Lov-
astatin is a highly potent competitive inhibitor of HMG-CoA
reductase [26] that mimics the mevaldyl-CoA thiohemiacetal
in the two-step reduction of HMG-CoA to mevalonic acid
(MA) [27]. Previous research by Crowell and Salaz [26]
suggested the capacity of low lovastatin concentrations (up
to 10 WM) to speci¢cally inhibit the cytokinin isoprenoid
side-chain synthesis. At higher concentrations (s 20 WM) lov-
astatin also inhibits the less sensitive MA-derived pathways
for the production of abscisic acid, gibberellins, ubiquinone,
sterols, carotenoids and many other isoprenoid compounds
[26^28], causing an irreversible arrest of cellular development
[26].
In this study, we show that the addition of low lovastatin
concentrations during G2 of an aphidicolin-synchronised to-
bacco BY-2 suspension culture, drastically reduces both the
accumulation of Z and the G2-M transition. Out of various
cytokinins as well as cyclic AMP and a synthetic auxin, only
zeatin was proven to e¡ectively reverse the inhibiting e¡ect of
lovastatin on mitosis. Our ¢ndings point to Z as a highly
speci¢c triggering factor for G2-M transition in tobacco BY-
2 cells.
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2. Materials and methods
2.1. Chemicals
AB-batches from Sigma (Bornem, Belgium) and ICN (Asse, Bel-
gium) were used. Cytokinins, NAA, BA and cAMP were delivered by
Sigma (Bornem, Belgium). All cytokinin-deuterated tracers ([2H5]Z,
[2H5]ZR, [2H5]Z9G, [2H5]ZOG, [2H5]ZROG, [2H6]2iP, [2H6]iPA,
[2H6]2iP9G, [2H3]DZ, [2H3]DZR) were purchased from Apex (Honi-
ton, UK). Lovastatin lactone was kindly provided by Merck (Rah-
way, NJ, USA) and MA lactone (DL-3,5-hydroxy-3-methyl-5-valero-
lactone) was bought from Sigma (Bornem, Belgium). The lactone
rings of lovastatin (lactone form) and MA lactone were hydrolysed
before application as described by Crowell and Salaz [26].
2.2. Culture maintenance and synchronisation
Tobacco BY-2 cell suspension cultures grew in Murashige and
Skoog medium (Duchefa, Haarlem, The Netherlands), which was en-
riched with sucrose (30 g/l), KH2PO4 (200 mg/l), thiamine (1 mg/l)
and with 0.2 mg/l of the synthetic auxin 2,4-dichlorophenoxyacetic
acid (2,4-D). Culture maintenance and synchronisation were con-
ducted as described by Nagata et al. [22]. Brie£y, an end concentra-
tion of 5 mg/ml of aphidicolin (AB) was added to fresh medium to
which 1:10 (v/v) of stationary culture was transferred. After 24 h, the
drug was removed by extensive washing and the cells were re-sus-
pended in fresh medium. At either 3 or 4.5 h after AB release, aliquots
of the culture were supplemented with the di¡erent substances of
interest. Samples for cytokinin analysis (4 ml, corresponding to
þ 0.25 gfw) were taken and left to sediment on ice, the supernatant
was removed and the fresh weight was recorded. Afterwards, they
were immediately frozen in liquid N2 and stored at 370‡C until ex-
traction.
2.3. Determination of the MI
Cells were ¢xed in PBS-bu¡ered paraformaldehyde/glutaraldehyde
(3% (w/v)/0.5% (v/v)) at 4‡C and stained with DAPI after a rinse in
PBS. Nuclei from late prophase to early telophase were scored in 500
cells by means of UV-£uorescence microscopy (Leitz dialux).
2.4. Extraction, puri¢cation and quantitative electrospray LC-MS/MS
analysis of cytokinins
Frozen cells were ground in liquid nitrogen and extracted overnight
at 320‡C in Bieleski solvent (CHCl3/CH2OH/H2O/HCOOH,
5:12:2:1, v/v) [29]. Deuterated cytokinins were added as internal
standards (5 pmol each). Solid-phase extraction and immuno-a⁄nity
puri¢cation were performed as described [30]. The samples thus ob-
tained were stored at 370‡C until analysis by (+ES) LC-MS/MS.
After dissolving the samples in 40 Wl of loading bu¡er (250 WM
tetrabutyl ammonium bromide (TBAB)+1 mM NH4Ac), cytokinins
were quanti¢ed by means of a capillary column-switching chromato-
graphic set-up combined with an on-line mass spectrometer according
to Witters et al. (in press). Five microliters of cytokinin samples were
injected in the LC set-up and pre-concentrated on a capillary pre-
column (C18, 5U0.5 mm internal diameter) using loading bu¡er as
a mobile phase (£ow rate 20 Wl/min, pH 6.6). After 5 min the pre-
column was back£ushed to the analytical column (C18, 150U0.3 mm
internal diameter) using a mobile phase containing 0.625% (v/v)
CH3COOH and 80% MeOH (£ow rate 10 Wl/min, pH 3.5). Tandem
mass spectrometry allowed analysis and quanti¢cation of the cytoki-
nins by means of their diagnostic transitions under a multiple reaction
monitoring mode [31]. Endogenous cytokinin concentrations were cal-
culated following the internal standard ratio method.
3. Results
3.1. E¡ect of lovastatin and mevalonic acid on mitosis
Since this research focused on the importance of cytokinins
for G2-M transition, lovastatin was added at either 3 or 4.5 h
after AB release (early or late G2) [32]. The e¡ect of di¡erent
lovastatin concentrations (1, 5 and 10 WM), given in late G2
(4.5 h), on the MI values of AB-synchronised cells is presented
in Fig. 1. In absence of lovastatin, the MI reached 40% at 7 h
after release from AB block.
Addition of 1 WM of lovastatin at 4.5 h hardly a¡ected the
MI until 6 h after AB release, whereas both 5 and 10 WM
caused a 40% reduction in MI measured at that time. At
7 h, an abrupt drop was observed (MI6 10%) for all concen-
trations applied. A minor yet signi¢cant fraction of cells was
not a¡ected by lovastatin and proceeded normally through
mitosis, since DAPI-staining of the DNA revealed no arrest
between late prophase and telophase in presence of lovastatin.
MA (6 mM) applied together with 1 or 10 WM lovastatin
was able to restore MI values at 7 h to 25% and 20% respec-
tively.
3.2. Endogenous CK levels after lovastatin treatment
To determine the e¡ect of lovastatin (applied in late G2) on
cytokinin biosynthesis, endogenous levels of 13 di¡erent cyto-
FEBS 20064 9-4-98
Fig. 1. Di¡erential trial of lovastatin (L) concentrations. MI in
blank conditions (a) and in presence of 1 WM L (O), 5 WM L (+),
10 WM L (F), 1 WM L+6 mM MA (U) and 10 WM L+6 mM MA
(b).
Fig. 2. Rescue of lovastatin (L)-induced inhibition of mitosis. MI in
blank conditions (a) and in presence of 10 WM L (F), 10 WM L+8
WM Z (S), 10 WM L+8 WM ZR (b), 10 WM L+8 WM iPA (R),
10 WM L+8 WM iP (E), 10 WM L+8 WM DZ (P), 10 WM L+8 WM
kinetin (+), 10 WM L+8 WM cAMP (U), 10 WM L+8 WM BA (O),
10 WM L+8 WM NAA (3).
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kinins were analysed by capillary (+ES) LC-MS/MS, 6, 7 and
8 h after AB release (Table 1). In control conditions (no lov-
astatin applied), only Z (1700 pmol/gfw) and ZR (300 pmol/
gfw) showed enhanced levels coinciding with the mitotic max-
imum at 7 h. No accumulation was recorded for any of the
other cytokinins analysed. Addition of lovastatin (10 WM) at
late G2 drastically reduced the endogenous Z concentration to
a maximum of 60 pmol/gfw, 7 h after release from AB. A
minor, yet signi¢cant increase in endogenous Z (160 pmol/
gfw) and ZR (30 pmol/gfw) was observed upon supplementa-
tion of lovastatin with 6 mM MA, in accordance with the
observed partial rescue of the lovastatin-induced inhibition
of mitosis (Fig. 1).
The rather low and steady concentrations ranging between
0 and 30 pmol/gfw that were observed under control condi-
tions for GiP, iPA, iP, DZNG, DZR, DZ, iPAP, DZMP,
OGZ, were not dramatically altered by lovastatin treatment.
3.3. Rescue of lovastatin-induced inhibition of mitosis
The ability to overcome lovastatin-induced inhibition of
mitosis was tested for ¢ve isoprenoid cytokinins (Z, ZR,
iPA, iP, DZ), kinetin, BA, cAMP and NAA (a synthetic aux-
in). Each compound was tested at a concentration of 8 WM
added in combination with 10 WM of lovastatin at 4.5 h after
AB release. For each experimental condition the MI of 500
cells was scored (Fig. 2). A mitotic peak of 41% in control
conditions was reached at 6 h after release from AB block.
Addition of 10 WM lovastatin alone reduced the MI to about
18%. Only Z could reverse the e¡ect of lovastatin on mitosis
(MI = 38%). Values measured for all the other treatments (lov-
astatin+ZR, iPA, iP, DZ, kinetin, cAMP, BA or NAA) re-
mained close to those encountered when only lovastatin was
added.
In order to test whether application of lovastatin in early
G2 would prevent more BY-2 cells to progress through mito-
sis 10 WM of lovastatin was added 3 h after AB release (Fig.
3). This lovastatin treatment (early G2) resulted in a similar
partial inhibition of the MI as was observed when lovastatin
was added at late G2 (Fig. 1). Again, adding Z at 4.5 h after
AB release to lovastatin treated BY-2 cells completely restored
the MI index to control values, whereas addition of DZ had
no signi¢cant e¡ect on the lovastatin-induced inhibition of
mitosis.
4. Discussion
In contrast to wild-type tobacco cell cultures [33] tobacco
BY-2 cells only need exogenously supplied auxin to proceed
through the cell cycle [22]. This feature can be directly linked
to the kinetics of endogenous cytokinins in aphidicolin-
synchronised BY-2 cell suspension cultures [23,24]. LC-MS/
MS analyses showed a transient accumulation of zeatin-type
cytokinins at G2-M transition [25]. Our study wishes to inves-
tigate the possible causal relationship between the accumula-
tion of Z-type cytokinins and the progression through this
particular stage of the cell cycle. Previously Crowell and Salaz
[26] have shown that low concentrations of lovastatin inhib-
ited the growth of tobacco BY-2 cells, a phenomenon that
they related to a putative inhibition of the cytokinin biosyn-
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Table 1
Endogenous cytokinin levels (pmol/gfw) during M phase of a
synchronised TBY-2 culture (C) and e¡ect of 10 WM lovastatin (L)
and 10 WM lovastatin+6 mM mevalonic acid (MA) on endogenous
cytokinin (CK) concentrations
CK Time after Conditions
release from
AB block (h) C L L+MA
Z 6 11 1 2
7 1700 60 160
8 14 31 14
DZ 6 1 6 1 1
7 7 4 12
8 6 1 2 1
iP 6 6 1 6 1 6 1
7 15 2 3
8 2 3 1
ZR 6 1 6 1 6 1
7 300 8 29
8 2 16 1
DZR 6 1 4 16
7 9 3 3
8 1 5 4
iPA 6 6 1 1 6 1
7 4 1 1
8 1 3 1
ZNG 6 6 1 1 6 1
7 2 6 1 5
8 6 1 1 6 1
ZNOG 6 16 4 4
7 3 3 3
8 2 3
DZG 6 6 1 3 6 1
7 6 1 6 1 5
8 6 1 1 6 1
iPNG 6 1 6 1 6 1
7 1 6 1 6 1
8 1 1 6 1
ZRP 6 6 1 6 1 4
7 10 3 3
8 28 7 3
DZRP 6 6 1 6 1 6 1
7 6 1 6 1 6 1
8 6 1 6 1 6 1
iPAP 6 28 9 3
7 2 2 2
8 2 2 1
Fig. 3. E¡ect of addition of lovastatin (L) at 3 h instead of 4.5 h
after release from AB. MI in blank conditions (a) and in presence
of 10 WM L (F), 10 WM L+8 WM Z (S), 10 WM L+8 WM DZ (P).
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thesis. Adding di¡erent concentrations at late G2 (Fig. 1)
con¢rmed the inhibitory e¡ect of lovastatin. A large popula-
tion of cells was arrested before mitosis. At the same time a
clear-cut decreased endogenous concentration of zeatin-type
cytokinins at the G2-M transition was observed (Table 1).
This inhibitory e¡ect could partially be reversed by adding
mevalonic acid, indicating that the observed accumulation
of zeatin-type cytokinins at the G2-M transition resulted
from a sharply controlled enhanced biosynthesis. The LC-
MS/MS data quantitatively prove the e⁄ciency of lovastatin
as a tool for the suppression of cytokinin biosynthesis in plant
cells.
Remarkable was the occurrence of a minor yet signi¢cant
population of cells, which apparently were not a¡ected by
lovastatin, even when given at early G2. This phenomenon
is possibly related to the observation that even in presence
of 10 WM lovastatin, the mevalonic acid synthesis is only
partially inhibited, or alternatively that a fraction of cells,
due to cluster formation, was not reached by the added lov-
astatin. In both cases a reduced endogenous zeatin concentra-
tion in G2-M transition, as shown in Table 1, would be the
consequence. If the endogenous zeatin concentration in all
cells were to be reduced, this would have as a consequence
that a sub-population of cells is characterised by a higher
cytokinin sensitivity. This would allow them to proceed
through mitosis at lower cytokinin concentrations in compar-
ison with the population of cells, which are arrested by lova-
statin.
In order to substantiate the need of BY-2 cells for enhanced
cytokinin levels to pass G2-M transition, various cytokinins
were tested for their ability to complement the lovastatin in-
hibition (Fig. 2). Among all tested cytokinins (Z, ZR, DZ, iP,
iPA, BA, kinetin) in the presence of lovastatin, only Z e¡ec-
tively restored MI near control values (no lovastatin added).
Neither cAMP [34] nor NAA had any e¡ect. By means of
uptake experiments with tritium labelled compounds, the con-
clusion could be drawn that the observed di¡erences in be-
haviour of the applied cytokinins were not due to an impaired
uptake of the less e¡ective compounds (data not shown).
For the ¢rst time, all these observations point to a stringent
structure-speci¢c e¡ect (Z only) rather than an overall func-
tion-speci¢c e¡ect of cytokinins on G2-M transition in tobac-
co BY-2 cells. More emphasis is thereby put on the need for
an accurately regulated zeatin metabolism during G2-M tran-
sition [25] and the existence of a putative zeatin-speci¢c re-
ceptor.
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